About Joel
Joel L. Nitzkin serves as a consultant to R Street, shaping much of their tobacco control policy, and speaking on behalf of such policy to state and local authorities, the American Medical Association and federal authorities.
Joel is a public health physician and is board certified as a specialist in preventive medicine. He has been a local health director, a state health director and president of two national public health organizations. He has been active in the tobacco control arena since the 1970s and played a lead role in developing and securing passage of early anti-smoking legislation in New York State and Louisiana.
He is currently in the private practice of public health as a health policy consultant. In this capacity, he has taken on a number of research and teaching assignments for federal, state and local public health agencies; assisted with accreditation of a managed care organization; and done substantial expert witness work related to communicable disease control, disaster response, health care quality, and tobacco control. He also served as the co-chair of the Tobacco Control Task Force of the American Association of Public Health Physicians.
Joel has a master’s degree in epidemiology from UC-Berkeley, a master’s and doctorate in public administration from Nova Southeastern University and his M.D. from Wayne State University School of Medicine.
For general and media inquiries and to book our experts, please contact: pr@rstreet.org
Research from Joel
R Street policy on tobacco harm reduction
E-cig tipping points vs. FDA deeming regulations
What drives tobacco-control policy?
H.R. 2058 and the regulation of e-cigarettes
E-cigarettes: A life-saving technology or a way for tobacco companies to re-normalize smoking in American society?
E-cigarette primer for state and local lawmakers
The case in favor of e-cigarettes for tobacco harm reduction
The promise of e-cigarettes for tobacco harm reduction
Reducing smoking: A guide for state policy makers
R Street policy on tobacco harm reduction
E-cig tipping points vs. FDA deeming regulations
What drives tobacco-control policy?
H.R. 2058 and the regulation of e-cigarettes
E-cigarettes: A life-saving technology or a way for tobacco companies to re-normalize smoking in American society?
E-cigarette primer for state and local lawmakers
The case in favor of e-cigarettes for tobacco harm reduction
The promise of e-cigarettes for tobacco harm reduction
Reducing smoking: A guide for state policy makers
R Street policy on tobacco harm reduction
Commentary from Joel
View all
Is Science or Policy Preference Leading the Way? Comments on the FDA Medicinal Nicotine Webcast
The FDA’s words and actions do not match
Letter concerning expanded federal campaign to discourage use of e-cigarettes
Is Science or Policy Preference Leading the Way? Comments on the FDA Medicinal Nicotine Webcast
The FDA’s words and actions do not match
Letter concerning expanded federal campaign to discourage use of e-cigarettes
bool(true)
bool(true)
string(2) "50"
Support Our Work
Your donation helps us engage in policy research and outreach in support of free markets and limited, effective government across the country.